Evaluating long-term outcomes of stereotactic radiotherapy for ventricular tachycardia
Cardiac RadiothErapy for VEntricular Tachycardia II - a Prospective Observational Cohort Study
This study is testing if a special type of radiation treatment can help people with hard-to-treat ventricular tachycardia feel better and stay safe over the long term.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Universitaire Ziekenhuizen KU Leuven Academic / other |
| Locations | 1 site (Leuven) |
| Trial ID | NCT06744530 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the long-term efficacy and safety of stereotactic radiotherapy ablation (STAR) in patients suffering from therapy-refractory ventricular tachycardia (VT). By focusing on patients who are eligible for STAR based on a multidisciplinary discussion, the study seeks to fill the gap in knowledge regarding the long-term outcomes of this treatment approach. Participants will be monitored for their responses and any adverse effects following the intervention, contributing valuable data to the field of cardiac care.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with therapy-refractory ventricular tachycardia who are eligible for stereotactic radiotherapy based on a multidisciplinary evaluation.
Not a fit: Patients who may not benefit from this study include those with contraindications for STAR, such as pregnancy, previous cardiac radiotherapy, or a life expectancy of less than six months without VT.
Why it matters
Potential benefit: If successful, this study could provide critical insights into the long-term effectiveness and safety of STAR for patients with refractory ventricular tachycardia.
How similar studies have performed: While stereotactic radiotherapy has become a standard care option, this study aims to provide new insights into its long-term outcomes, indicating a novel approach in this specific context.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Eligible for STAR for therapy-refractory VT based on a multidisciplinary discussion * Ability to give a written informed consent and willingness to return for follow-up Exclusion Criteria: * Contra-indications for STAR, including pregnancy or breastfeeding, previous radiotherapy with cardiac involvement, life-expectancy \< 6 months in the absence of VT * Any condition that is deemed a contraindication in the judgment of the investigators
Where this trial is running
Leuven
- UZ Leuven — Leuven, Belgium (Recruiting)
Study contacts
- Study coordinator: Bert Vandenberk, MD PhD
- Email: bert.vandenberk@uzleuven.be
- Phone: +3216338686
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.